Skip to main content
Gustavo Kinrys, MD, Psychiatry, Boston, MA, Massachusetts General Hospital

GustavoDKinrysMD

Psychiatry Boston, MA

Psychopharmacology, Clinical Pharmacology, Clinical Informatics

Medical Director

Dr. Kinrys is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kinrys' full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Research, 2001 - 2003
  • Massachusetts General Hospital/McLean Hospital
    Massachusetts General Hospital/McLean HospitalChief Residency, Psychiatry, 2000 - 2002
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Psychiatry, 1998 - 2002
  • Faculdade de Medicina da Universidade Federal do Rio de Janeiro
    Faculdade de Medicina da Universidade Federal do Rio de JaneiroClass of 1996

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2001 - 2024
  • MN State Medical License
    MN State Medical License 2001 - 2002

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Research Paper Tachyphylaxis in Major Depressive Disorder: A Review of the Current State of Research  
    Gustavo Kinrys, Andrew A Nierenberg, George I Papakostas, David Mischoulon, Maurizio Fava, Marlene P Freeman, ScienceDirect

Press Mentions

  • Demand for Virtual Mental Healthcare Is Soaring. Here Are Key Trends on Who Is Using It and Why
    Demand for Virtual Mental Healthcare Is Soaring. Here Are Key Trends on Who Is Using It and WhyOctober 23rd, 2020
  • Teladoc Health Data Shows Broadening Mental Health Care Demand
    Teladoc Health Data Shows Broadening Mental Health Care DemandOctober 21st, 2020
  • Antidepressant with Novel Mechanism of Action Appears Safe and Effective in Phase 1b Clinical Trial
    Antidepressant with Novel Mechanism of Action Appears Safe and Effective in Phase 1b Clinical TrialDecember 8th, 2015

Hospital Affiliations